3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
45
Carboplatin
33
Bevacizumab
17
liposomal doxorubicin
15
Topotecan
12
Taxes
10
Gemcitabine
10
Drug Therapy
6
Cisplatin
6
rucaparib
5
mirvetuximab soravtansine
5
Docetaxel
5
Immunoglobulin G
4
Doxorubicin
4
Disulfides
4
trebananib
3
pembrolizumab
3
olaparib
3
Saline Solution
3
Neoadjuvant Therapy
3
Hyperthermic Intraperitoneal Chemotherapy
3
Dexamethasone
3
CP protocol
3
niraparib
2
cediranib
2
Tamoxifen
2
Specimen Handling
2
Letrozole
2
Glucose
2
Cytoreduction Surgical Procedures
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Fallopian Tube Neoplasms
×
Histamine H2 Antagonists
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled